Overview

PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of tadalafil for the treatment of pulmonary arterial hypertension.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
ICOS Corporation
Treatments:
Tadalafil